Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment

Clinical and Translational Oncology

Volumn 13, Issue 12, 2011, Pages 889-898

  Schroeder, Petra ^a   Lindemann, Carsten ^a   Dettmar, Kirsten ^b   Brieger, Jürgen ^c   Gosepath, Jan ^d   Pogorzelski, Benjamin ^d   Seimetz, Diane ^b   Atz, Judith ^b  

^a BIONTECH AG   (Germany)

^b Fresenius Biotech   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Catumaxomab; Chemotherapy; Ertumaxomab; HNSCC; Immunotherapy; Trifunctional antibody

Indexed keywords

CATUMAXOMAB; CISPLATIN; ERTUMAXOMAB; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL ASSAY; CELL COUNT; CELL ISOLATION; CELL KILLING; CLINICAL ARTICLE; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EFFECTOR CELL; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MEDIATOR; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; SQUAMOUS CELL CARCINOMA; SUPERNATANT; TARGET CELL;

AGED; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY; CISPLATIN; CYTOKINES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 84856034032     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0751-5     Document Type: Article

References (40)

1. Köninki K, Barok M, Tanner M et al (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294:211-219
2. Ciavarella S, Milano A, Dammacco F, Silvestris F (2010) Targeted therapies in cancer. BioDrugs 24:77-88
3. Gall JM, Davol PA, Grabert RC et al (2005) T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 33:452-459 (Pubitemid 40387628)
4. Watanabe M, Wallace PK, Keler T et al (1999) Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat 53:199-207 (Pubitemid 29209889)
5. Wimberger P, Xiang W, Mayr D et al (2003) Efficient tumour cell lysis by autologous, tumourresident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. Int J Cancer 105:241-248 (Pubitemid 36505328)
6. Chan JK, Hamilton CA, Cheung MK et al (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12:1859-1867
7. Reusch U, Sundaram M, Davol PA et al (2006) Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12:183-190 (Pubitemid 43166193)
8. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36:458-467
9. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209-2221
10. Zeidler R, Reisbach G, Wollenberg B et al (1999) Simultaneous activation of T-cells and accessory cells by a new class of intact bi-specific antibody results in efficient tumor cell killing. J Immunol 163:1246-1252 (Pubitemid 29352740)
11. Zeidler R, Mysliwietz J, Csanady M et al (2000) The Fc-region of a new class of intact bi-specific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumor cells. Br J Cancer 83:261-266 (Pubitemid 30411727)
12. Zeidler R, Mayer A, Gires O et al (2001) TNFalpha contributes to the anti-tumor activity of a bispecific, trifunctional antibody. Anticancer Res 21:3499-3503 (Pubitemid 34224257)
13. Ruf P, Gires O, Jäger M et al (2007) Characterisation of the new EpCAM-specifi c antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 97:315-321 (Pubitemid 47196752)
14. Alanko S, Pelliniemi TT, Salmi TT (1992) Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer 69:1481-1486
15. Campbell MJ, Scott J, Maecker HT (2005) Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat 91:163-171 (Pubitemid 40684928)
16. Zignol M, Peracchi M, Tridello G et al (2004) Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer 101:635-641 (Pubitemid 38970616)
17. Robert F, Childs HA, Spencer SA et al (1999) Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Radiat Oncol 9:136-147 (Pubitemid 29190424)
18. Alanko S, Salmi TT, Pelliniemi TT (1994) Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 11:281-292 (Pubitemid 24153140)
19. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50
20. Standish LJ, Torkelson C, Hamill FA et al (2008) Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol 6:110-121
21. Peters GJ, van Triest B, Backus HH et al (2000) Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36:916-924 (Pubitemid 30214143)
22. Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7:2168-2181 (Pubitemid 32751613)
23. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498
24. Saridaki Z, Georgoulias V, Souglakos J (2010) Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 16:1177-1187
25. Han HS, Kim JS, Park JH et al (2009) Weekly paclitaxel and trastuzumab as a fi rst-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplifi cation as a predictive factor for effi cacy. J Korean Med Sci 24:910-917
26. Markasz L, Skribek H, Uhlin M et al (2008) Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 31:283-293 (Pubitemid 351441005)
27. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73
28. Zitvogel L, Apetoh L, Ghiringhelli F et al (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991-2001. Review (Pubitemid 351872317)
29. Wu X, Feng QM, Wang Y et al (2010) The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother 59:279-291
30. Friedman EJ (2002) Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8:1765-1780 (Pubitemid 34846202)
31. Chiriva-Internati M, Grizzi F, Pinkston J et al (2006) Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 42:89-95 (Pubitemid 44264512)
32. Hareyama M, Imai K, Ban T et al (1988) Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells - immunological study using monoclonal antibodies. Nippon Igaku Hoshasen Gakkai Zasshi 48:1572-1574
33. Gaugler MH, Squiban C, van der Meeren A et al (1997) Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int J Radiat Biol 72:201-209 (Pubitemid 27339415)
34. Garnett CT, Palena C, Chakraborty M et al (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64:7985-7994 (Pubitemid 39446933)
35. Kiewe P, Hasmüller S, Kahlert S et al (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085-3091 (Pubitemid 43837355)
36. Bokemeyer C, Heiss M, Gamperl H et al (2009) Safety of catumaxomab: cytokine-release-related symptoms as a possible predictive factor for effi cacy in a pivotal phase II/III trial in malignant ascites. J Clin Oncol 27[Suppl]:Abstract 3036
37. Saito T, Berens ME, Welander CE (1986) Direct and indirect effects of human recombinant gamma-interferon on tumor cells in a clonogenic assay. Cancer Res 46:1142-1147 (Pubitemid 16048245)
38. Gronau SS, Schmitt M, Thess B et al (2005) Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 27: 376-382 (Pubitemid 40593891)
39. Schmitt M, Schmitt A, Reinhardt P et al (2004) Opsonization with a trifunctional bispecifi c (alphaCD3 × alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25:841-848
40. Hirschhaeuser F, Leidig T, Rodday B et al (2009) Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen 14:980-990